@aktiego.bsky.socialNurExone partnered with NanoPass to test its exosomes with an FDA-cleared delivery device for eye and skin uses, then got shareholder approval for a share consolidation tied to a future US listing push.
Analysis at aktiego.com.
This is not financial advice. DYOR.